Cargando…
Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage
OBJECTIVES: The benefit of adjuvant chemotherapy in patients with localized uterine leiomyosarcoma (LMS) remains unclear due to a lack of randomized studies and data only from small retrospective series to rely on. We sought to identify factors associated with the administration of chemotherapy and...
Autores principales: | Patel, Dhara, Handorf, Elizabeth, von Mehren, Margaret, Martin, Lainie, Movva, Sujana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387708/ https://www.ncbi.nlm.nih.gov/pubmed/30881199 http://dx.doi.org/10.1155/2019/3561501 |
Ejemplares similares
-
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020) -
Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma
por: Chantharasamee, Jomjit, et al.
Publicado: (2022) -
Uterine Leiomyosarcoma
por: Byar, Katherine L., et al.
Publicado: (2022) -
Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma
por: Momtahen, Shabnam, et al.
Publicado: (2016) -
Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
por: Movva, Sujana, et al.
Publicado: (2015)